Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Hairpin Ribozyme Genes Curtail Alcohol Drinking: from Rational Design to in vivo Effects in the Rat.

Sapag A, Irrazábal T, Lobos-González L, Muñoz-Brauning CR, Quintanilla ME, Tampier L.

Mol Ther Nucleic Acids. 2016;5:e335. doi: 10.1038/mtna.2016.41.

2.

Hairpin Ribozyme Genes Curtail Alcohol Drinking: from Rational Design to in vivo Effects in the Rat.

Sapag A, Irrazábal T, Lobos-González L, Muñoz-Brauning CR, Quintanilla ME, Tampier L.

Mol Ther Nucleic Acids. 2016 Jul 12;5(7):e335. doi: 10.1038/mtna.2016.41.

3.

A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.

Poersch A, Grassi ML, Carvalho VP, Lanfredi GP, Palma Cde S, Greene LJ, de Sousa CB, Carrara HH, Candido Dos Reis FJ, Faça VM.

J Proteomics. 2016 Aug 11;145:226-36. doi: 10.1016/j.jprot.2016.05.005.

PMID:
27222041
4.

Therapeutic Strategies for the Treatment of Alcoholic Hepatitis.

Singal AK, Shah VH.

Semin Liver Dis. 2016 Feb;36(1):56-68. doi: 10.1055/s-0036-1571297. Review.

PMID:
26870933
5.

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.

Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, Jerlhag E, Engel JA, Hodgkinson CA, Egli M, Lopez MF, Becker HC, Goldman D, Heilig M, Ramchandani VA, Leggio L.

Transl Psychiatry. 2015 Jun 16;5:e583. doi: 10.1038/tp.2015.68.

6.

MicroRNAs in fatty liver disease.

Sobolewski C, Calo N, Portius D, Foti M.

Semin Liver Dis. 2015 Feb;35(1):12-25. doi: 10.1055/s-0034-1397345. Review.

PMID:
25632931
7.

[Alcohol dependence mediated by monoamine neurotransmitters in the central nervous system].

Yang X, Zhang H, Lai J.

Yi Chuan. 2014 Jan;36(1):11-20. Review. Chinese.

PMID:
24846914
8.

Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Harvey RJ, Yee BK.

Nat Rev Drug Discov. 2013 Nov;12(11):866-85. doi: 10.1038/nrd3893. Review.

PMID:
24172334
9.

Glutamatergic targets for new alcohol medications.

Holmes A, Spanagel R, Krystal JH.

Psychopharmacology (Berl). 2013 Oct;229(3):539-54. doi: 10.1007/s00213-013-3226-2. Review.

10.

Acamprosate suppresses ethanol-induced place preference in mice with ethanol physical dependence.

Kurokawa K, Mizuno K, Shibasaki M, Higashioka M, Oka M, Hirouchi M, Ohkuma S.

J Pharmacol Sci. 2013;122(4):289-98.

11.

Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Gorini G, Harris RA, Mayfield RD.

Neuropsychopharmacology. 2014 Jan;39(1):104-30. doi: 10.1038/npp.2013.182. Review.

12.

Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease.

Kong X, Feng D, Mathews S, Gao B.

J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:56-60. doi: 10.1111/jgh.12032. Review.

13.

Challenges in cancer vaccine development for hepatocellular carcinoma.

Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM.

J Hepatol. 2013 Oct;59(4):897-903. doi: 10.1016/j.jhep.2013.05.031. Review. Erratum in: J Hepatol. 2014 Jan;60(1):237.

14.

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Cooper ME, Regnell SE.

Br J Clin Pharmacol. 2014 Jan;77(1):21-30. doi: 10.1111/bcp.12102. Review.

15.

Agmatine attenuates acquisition but not the expression of ethanol conditioned place preference in mice: a role for imidazoline receptors.

Sameer SM, Chakraborty SS, Ugale RR.

Behav Pharmacol. 2013 Apr;24(2):87-94. doi: 10.1097/FBP.0b013e32835efc46.

PMID:
23399882
16.

Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in vivo evidence, molecular targets, and clinical relevance.

Bishayee A, Thoppil RJ, Waghray A, Kruse JA, Novotny NA, Darvesh AS.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1191-232. Review.

PMID:
22873222
17.

Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders.

Davies DL, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J, Olsen RW.

Alcohol Clin Exp Res. 2013 Jan;37(1):8-15. doi: 10.1111/j.1530-0277.2012.01846.x. Review.

18.

Novel medication targets for the treatment of alcoholism: preclinical studies.

Rezvani AH, Lawrence AJ, Arolfo MP, Levin ED, Overstreet DH.

Recent Pat CNS Drug Discov. 2012 Aug;7(2):151-62. Review.

PMID:
22574676
19.

Cholinergic receptor system as a target for treating alcohol abuse and dependence.

Rahman S, Prendergast MA.

Recent Pat CNS Drug Discov. 2012 Aug;7(2):145-50. Review.

PMID:
22574675
20.

Polyamine modulation of NMDARs as a mechanism to reduce effects of alcohol dependence.

Barron S, Lewis B, Wellmann K, Carter M, Farook J, Ring J, Rogers DT, Holley R, Crooks P, Littleton J.

Recent Pat CNS Drug Discov. 2012 Aug;7(2):129-44. Review.

PMID:
22574674
Items per page

Supplemental Content

Loading ...
Support Center